284 related articles for article (PubMed ID: 27999358)
1. Review of Toxic Epidermal Necrolysis.
Harris V; Jackson C; Cooper A
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999358
[TBL] [Abstract][Full Text] [Related]
2. A Review of the Pathogenesis of Toxic Epidermal Necrolysis.
Kinoshita Y; Saeki H
J Nippon Med Sch; 2016; 83(6):216-222. PubMed ID: 28133001
[TBL] [Abstract][Full Text] [Related]
3. [Epidermal necrolysis: mechanisms of keratinocyte apoptosis].
Roujeau JC; Gélard K; Bensussan A
Med Sci (Paris); 2006 Feb; 22(2):188-91. PubMed ID: 16457761
[TBL] [Abstract][Full Text] [Related]
4. [News in severe clinical adverse drug reactions: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)].
Martínez-Cabriales SA; Gómez-Flores M; Ocampo-Candiani J
Gac Med Mex; 2015; 151(6):777-87. PubMed ID: 26581536
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic proteins and therapeutic targets in severe cutaneous adverse reactions.
Su SC; Chung WH
Toxins (Basel); 2014 Jan; 6(1):194-210. PubMed ID: 24394640
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis.
Khalili B; Bahna SL
Ann Allergy Asthma Immunol; 2006 Sep; 97(3):272-80; quiz 281-3, 320. PubMed ID: 17042130
[TBL] [Abstract][Full Text] [Related]
7. Genetic markers and danger signals in stevens-johnson syndrome and toxic epidermal necrolysis.
Chung WH; Hung SI
Allergol Int; 2010 Dec; 59(4):325-32. PubMed ID: 20962567
[TBL] [Abstract][Full Text] [Related]
8. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis.
Chung WH; Hung SI; Yang JY; Su SC; Huang SP; Wei CY; Chin SW; Chiou CC; Chu SC; Ho HC; Yang CH; Lu CF; Wu JY; Liao YD; Chen YT
Nat Med; 2008 Dec; 14(12):1343-50. PubMed ID: 19029983
[TBL] [Abstract][Full Text] [Related]
9. Immunologic Mediators in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
Saeed HN; Chodosh J
Semin Ophthalmol; 2016; 31(1-2):85-90. PubMed ID: 26959133
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and management of Stevens-Johnson syndrome/toxic epidermal necrolysis.
Noe MH; Micheletti RG
Clin Dermatol; 2020; 38(6):607-612. PubMed ID: 33341195
[TBL] [Abstract][Full Text] [Related]
11. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the Era of Systems Medicine.
Chen CB; Wang CW; Chung WH
Methods Mol Biol; 2022; 2486():37-54. PubMed ID: 35437717
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the potential role of cytokines in toxic epidermal necrolysis.
Nassif A; Moslehi H; Le Gouvello S; Bagot M; Lyonnet L; Michel L; Boumsell L; Bensussan A; Roujeau JC
J Invest Dermatol; 2004 Nov; 123(5):850-5. PubMed ID: 15482470
[TBL] [Abstract][Full Text] [Related]
13. Immunological response in Stevens-Johnson syndrome and toxic epidermal necrolysis.
Abe R
J Dermatol; 2015 Jan; 42(1):42-8. PubMed ID: 25355273
[TBL] [Abstract][Full Text] [Related]
14. [Mechanisms of Severe Cutaneous Adverse Reactions and a New Treatment Strategy].
Saito Y; Nakamura R
Yakugaku Zasshi; 2019; 139(12):1557-1562. PubMed ID: 31787645
[TBL] [Abstract][Full Text] [Related]
15. Death ligand TRAIL, secreted by CD1a+ and CD14+ cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis.
de Araujo E; Dessirier V; Laprée G; Valeyrie-Allanore L; Ortonne N; Stathopoulos EN; Bagot M; Bensussan A; Mockenhaupt M; Roujeau JC; Tsapis A
Exp Dermatol; 2011 Feb; 20(2):107-12. PubMed ID: 21255088
[TBL] [Abstract][Full Text] [Related]
16. Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis.
Schwartz RA; McDonough PH; Lee BW
J Am Acad Dermatol; 2013 Aug; 69(2):173.e1-13; quiz 185-6. PubMed ID: 23866878
[TBL] [Abstract][Full Text] [Related]
17. TNF-α and IFN-γ are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis.
Viard-Leveugle I; Gaide O; Jankovic D; Feldmeyer L; Kerl K; Pickard C; Roques S; Friedmann PS; Contassot E; French LE
J Invest Dermatol; 2013 Feb; 133(2):489-98. PubMed ID: 22992806
[TBL] [Abstract][Full Text] [Related]
18. [Recent progress in research of pathogeneses of Stevens-Johnson syndrome and toxic epidermal necrolysis].
Gao TT; Long Q
Zhonghua Yan Ke Za Zhi; 2016 Sep; 52(9):708-13. PubMed ID: 27647252
[TBL] [Abstract][Full Text] [Related]
19. Would cyclosporin A be beneficial to mitigate drug-induced toxic epidermal necrolysis?
Paquet P; Piérard GE
Dermatology; 1999; 198(2):198-202. PubMed ID: 10325481
[TBL] [Abstract][Full Text] [Related]
20. Toxic epidermal necrolysis: current evidence, practical management and future directions.
Chave TA; Mortimer NJ; Sladden MJ; Hall AP; Hutchinson PE
Br J Dermatol; 2005 Aug; 153(2):241-53. PubMed ID: 16086734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
